Allogeneic transplantation and frontline therapy shape survival outcomes in secondary AML: Real-world epidemiology and prognostic insights
Por:
Coll, R, Brey, N, Sturla, AL, Viñas, J, Arnan, M, Pomares, H, Vives, S, Balarí, AS, Sancho, JM and Gallardo, D
Publicada:
1 dic 2025
Ahead of Print:
1 dic 2025
Resumen:
Filiaciones:
Brey, N:
Hosp Josep Trueta, Girona, Spain
Sturla, AL:
Inst Catala Oncol Hospitalet, Idibell, Hospitalet, Spain
Viñas, J:
Hosp Badalona Germans Trias & Pujol, Badalona, Spain
Arnan, M:
Inst Catala Oncol Hospitalet, IDIBELL, Barcelona, Spain
Pomares, H:
Inst Catala Oncol Hospitalet, IDIBELL, Barcelona, Spain
:
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
Balarí, AS:
Hosp Josep Trueta, Inst Catala Oncol, Girona, Spain
Inst Catala Oncol Hospitalet, IDIBELL, Barcelona, Spain
:
Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
Gallardo, D:
Inst Catala Oncol Girona, Girona, Spain
|